Oxford Cancer Analytics
Oxford Cancer Analytics (OXcan) is a medtech company focused on transforming curative cancer treatments through early detection using a minimally invasive blood test powered by machine learning. Their DEcancer platform analyzes blood for cancer biomarkers, specifically focusing on lung cancer for initial market entry. OXcan aims to improve cancer management by offering an affordable and accurate screening method that leverages advanced proteomics and AI, positioning itself to detect cancers earlier when they are most curable. The company has secured significant funding, with $11 million raised in Series A and $3.7 million in seed funding, indicating strong investor confidence. OXcan is built by a multidisciplinary team with expertise in cancer research, clinical medicine, machine learning, and business, with key leaders recognized in Forbes' 30 Under 30 lists.
Oxford Cancer Analytics
Oxford Cancer Analytics (OXcan) is a medtech company focused on transforming curative cancer treatments through early detection using a minimally invasive blood test powered by machine learning. Their DEcancer platform analyzes blood for cancer biomarkers, specifically focusing on lung cancer for initial market entry. OXcan aims to improve cancer management by offering an affordable and accurate screening method that leverages advanced proteomics and AI, positioning itself to detect cancers earlier when they are most curable. The company has secured significant funding, with $11 million raised in Series A and $3.7 million in seed funding, indicating strong investor confidence. OXcan is built by a multidisciplinary team with expertise in cancer research, clinical medicine, machine learning, and business, with key leaders recognized in Forbes' 30 Under 30 lists.